Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 909-915

  Srirajaskanthan, Rajaventhan ^a   Shah, Tahir ^a   Watkins, Jennifer ^a   Marelli, Laura ^a   Khan, Korsa ^a   Caplin, Martyn E ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Epidermal growth factor receptor; HER 2; HER 3; HER 4; Immunohistochemistry; Neuroendocrine tumours; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; PARAFFIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL;

EID: 77949481258     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000714     Document Type: Article

References (42)

1. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 18: 1-11, 2004.
2. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3-S8, 2001.
3. Citri A, Skaria KB and Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 10: 54-65, 2003.
4. Casalini P, Iorio MV, Galmozzi E and Menard S: Role of HER receptors family in development and differentiation. J Cell Physiol 200: 343-350, 2004.
5. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2002.
6. Gullick WJ: The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 8: 75-82, 2001.
7. Koutsopoulos AV, Mavroudis D, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulias V and Stathopoulos EN: Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer 57: 193-200, 2007.
8. Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H and Moinfar F: Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol 101: 18-23, 2006.
9. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Lauter J, Lessig R, Krishnamurthi K, Ullrich A and Hengstler JG: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24: 4317-4323, 2006.
10. Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297, 2003.
11. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D and Economopoulos T: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6: 46, 2006.
12. Kamath S and Buolamwini JK: Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 26: 569-594, 2006.
13. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP and Caplin ME: Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 18: 355-360, 2006.
14. De Laurentiis M, Cancello G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, Caputo F, Accurso A and De PS: Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol 16 (Suppl 4): iv7-iv13, 2005.
15. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P and Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61-72, 2008.
16. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF and Burroughs AK: Carcinoid tumour. Lancet 352: 799-805, 1998.
17. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S and Brockhoff G: Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 8: R2, 2008.
18. Schmelz EM, Xu H, Sengupta R, Du J, Banerjee S, Sarkar FH, Rishi AK and Majumdar AP: Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. Cancer Res 67: 5389-5396, 2007.
19. Smeenk HG, Erdmann J, van DH, van MR, Hop WC, Jeekel J and van Eijck CH: Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig Surg 24: 38-45, 2007.
20. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM and Lloyd RV: Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 18: 1329-1335, 2005.
21. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J and Jensen RT: Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62: 3702-3710, 2002.
22. Wang DG, Johnston CF and Buchanan KD: Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 80: 668-675, 1997.
23. Yamaguchi M, Hirose K and Hirai N: HER2 expression in gastrointestinal carcinoid tumors: high in intestinal but not in gastric tumors. Surg Today 37: 270-271, 2007.
24. Roncalli M, Springall DR, Varndell IM, Gaitonde VV, Hamid Q, Ibrahim NB, Grimelius L, Wilander E, Polak JM and Coggi G: Oncoprotein immunoreactivity in human endocrine tumours. J Pathol 163: 117-127, 1991.
25. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY and Wiedenmann B: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401, 2006.
26. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY and Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451: 757-762, 2007.
27. Iddon J, Bundred NJ, Hoyland J, Downey SE, Baird P, Salter D, McMahon R and Freemont AJ: Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 191: 170-174, 2000.
28. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS and Storkel S: Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901, 2004.
29. Evers BM, Rady PL, Sandoval K, Arany I, Tyring SK, Sanchez RL, Nealon WH, Townsend CM Jr and Thompson JC: Gastrinomas demonstrate amplification of the HER-2/neu protooncogene. Ann Surg 219: 596-601, 1994.
30. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.
31. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264, 1997.
32. Lenferink AE, Pinkas-Kramarski R, Van de Poll ML, Van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, Van Zoelen EJ and Yarden Y: Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17: 3385-3397, 1998.
33. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6: 4217-4225, 2000.
34. Hellyer NJ, Cheng K and Koland JG: ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 333: 757-763, 1998.
35. Hopfner M, Sutter AP, Gerst B, Zeitz M and Scherubl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 89: 1766-1775, 2003.
36. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J and Tabernero J: New drug development in digestive neuroendocrine tumors. Ann Oncol 18: 1307-1313, 2007.
37. Hobday TJ, Mahoney M and Erlichman C: Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol 23: 4083, 2005.
38. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4): 31-39, 2002.
39. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 (Suppl 1): 25-32, 2000.
40. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J and Ling YH: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6: 4932-4938, 2000.
41. Gullick WJ: c-erbB-4/HER4: friend or foe? J Pathol 200: 279-281, 2003.
42. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J and Hachitanda Y: Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 185: 165-167, 2003.